The possible benefits and dangers of a vaccine program for CMV infection, especially congenital infection, cannot be rationally analyzed until more is known about the virus itself, including its manner of spread and the nature of host responses. Until then, trials with the experimental vaccines under development should be limited to patients at unusually high risk, such as those receiving renal transplants.